# US Chordoma Disease Market

> United States Chordoma Disease Market Research Report By End User (Hospital, Clinic, Cancer Care Centers) By Diagnosis (Biopsy, Imaging, Blood Tests) By Treatment (Chemotherapy, Radiation Therapy, Cryosurgery, Surgery, Targeted Therapy) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.91%
- **2024:** $ 911.4 Million
- **2025:** $ 956.15 Million
- **2035:** $ 1,544.5 Million
- **Key Players:** Bristol Myers Squibb (US), Novartis (CH), Eli Lilly and Company (US), Merck & Co. (US), Amgen (US), Bayer (DE), Pfizer (US), AstraZeneca (GB)

**Report ID:** MRFR/Pharma/17377-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-chordoma-disease-market-18923

---

## Market Summary

## US Chordoma Disease Market Highlighted Trends & Dynamics

The demand for diagnosis and treatment solutions for Chordoma disease in the United States has gained attention, reflecting increased awareness of this rare type of cancer and advancements in oncology. Chordoma is a slow-growing tumor that typically occurs along the spine, specifically in the bones of the skull base or spine. Due to its rarity and unique characteristics, accurate diagnosis is crucial for guiding appropriate treatment strategies. Advanced imaging techniques such as MRI and CT scans are often employed to visualize the tumor and assess its location and extent.

The rarity of Chordoma contributes to the challenges in its diagnosis and treatment. This rare cancer arises from remnants of the notochord, a structure present during embryonic development, and affects a relatively small number of individuals. The need for specialized diagnostic tools and treatment options for Chordoma is underscored by the limited understanding of the disease and the complexity of managing tumors in critical anatomical locations.

The COVID-19 pandemic has brought attention to the importance of maintaining continuity in cancer care, including rare diseases like Chordoma. The pandemic has highlighted the vulnerability of individuals with underlying health conditions, emphasizing the need for robust diagnostic capabilities and treatment options for rare and challenging cancers. The demand for solutions in the Chordoma disease market has been further emphasized by the global healthcare community's commitment to addressing the unique challenges posed by rare cancers and ensuring the best possible outcomes for patients.

Treatment for Chordoma often involves a multidisciplinary approach, including surgery, radiation therapy, and, in some cases, targeted therapies. The demand for these treatments is closely linked to the prevalence of Chordoma cases and ongoing research efforts aimed at developing more effective and targeted therapeutic strategies. Additionally, the need for supportive care, including pain management, rehabilitation, and psychosocial support, contributes to the overall demand for managing Chordoma comprehensively.

Collaborative efforts between oncologists, surgeons, radiation oncologists, and pharmaceutical companies play a vital role in shaping the Chordoma disease market. Research initiatives focused on understanding the molecular characteristics of Chordoma, identifying potential therapeutic targets, and developing innovative treatment modalities contribute to advancements in the field. Moreover, patient advocacy groups and educational campaigns aimed at increasing awareness about Chordoma and fostering collaboration among healthcare professionals contribute to early detection and improved patient outcomes.

The market's future trajectory is likely to be influenced by ongoing innovations in diagnostic technologies, therapeutic advancements, and an increased focus on personalized medicine. The integration of precision medicine approaches, including genetic profiling and targeted therapies, may revolutionize the treatment landscape for Chordoma. Additionally, advancements in imaging technologies and minimally invasive surgical techniques may further enhance the accuracy and efficiency of diagnosing and managing Chordoma.

## Market Drivers

### Rising Incidence of Chordoma Cases

This market is influenced by the rising incidence of chordoma cases in the United States. Recent epidemiological studies suggest that the annual incidence of chordoma is approximately 0.8 per million people, indicating a gradual increase in diagnosed cases. This rise may be attributed to improved diagnostic capabilities and heightened awareness among healthcare professionals. As more patients are diagnosed, the demand for effective treatment options is expected to grow. This trend is likely to stimulate investment in research and development, leading to the introduction of novel therapies and treatment modalities in the chordoma disease market. Additionally, the increasing number of clinical trials aimed at exploring new treatment avenues may further enhance the market landscape, providing patients with more options and potentially improving survival rates.

### Advancements in Surgical Techniques

The chordoma disease market is experiencing a notable shift due to advancements in surgical techniques. Innovations such as minimally invasive surgery and robotic-assisted procedures are enhancing the precision of tumor removal. These techniques not only improve patient outcomes but also reduce recovery times, which is crucial for chordoma patients. The integration of advanced imaging technologies, such as MRI and CT scans, allows for better preoperative planning and intraoperative navigation. As a result, the surgical success rate for chordoma excisions is increasing, which may lead to a higher demand for surgical interventions within the chordoma disease market. Furthermore, the growing number of specialized surgical centers dedicated to chordoma treatment is likely to contribute to market growth, as these facilities are equipped with the latest technologies and expertise to handle complex cases.

### Increased Patient Support Initiatives

This market is benefiting from increased patient support initiatives aimed at improving the quality of life for those affected by this rare cancer. Organizations dedicated to chordoma awareness and support are emerging, providing resources, education, and advocacy for patients and their families. These initiatives are crucial in fostering a supportive community and ensuring that patients have access to the latest information regarding treatment options. In 2025, it is projected that patient support organizations will expand their outreach efforts, potentially increasing patient engagement in clinical trials and treatment programs. This heightened awareness may lead to earlier diagnosis and intervention, positively impacting patient outcomes. As more patients become informed about their condition, the demand for specialized care and treatment options within the chordoma disease market is likely to rise.

### Regulatory Support for Innovative Therapies

Regulatory support for innovative therapies is emerging as a significant driver in the chordoma disease market. The U.S. Food and Drug Administration (FDA) has implemented various initiatives to expedite the approval process for treatments targeting rare diseases, including chordoma. Programs such as the Orphan Drug Designation and Breakthrough Therapy Designation are designed to encourage the development of novel therapies by providing incentives to pharmaceutical companies. This regulatory environment is likely to foster innovation and attract investment in the chordoma disease market. As a result, the time from discovery to market for new treatments may decrease, providing patients with faster access to potentially life-saving therapies. Furthermore, the collaboration between regulatory bodies and industry stakeholders is expected to enhance the overall landscape of treatment options available for chordoma patients.

### Growing Investment in Research and Development

Investment in research and development (R&D) is a critical driver for the chordoma disease market. Pharmaceutical companies and research institutions are increasingly allocating funds to explore new therapeutic approaches, including targeted therapies and immunotherapies. The U.S. government has also recognized the need for innovative treatments, providing grants and funding opportunities for research focused on rare cancers like chordoma. In 2025, it is estimated that R&D spending in the oncology sector will reach approximately $50 billion, with a portion dedicated to rare tumors. This influx of capital is likely to accelerate the pace of discovery and development of effective treatments for chordoma, thereby expanding the market. Furthermore, collaborations between academic institutions and biotech firms are fostering innovation, which may lead to breakthroughs in the understanding and treatment of chordoma.

## Future Outlook

The [Chordoma Disease Market](https://www.marketresearchfuture.com/reports/chordoma-disease-market-5784) is projected to grow at a 4.91% compound annual growth rate (CAGR) from 2025 to 2035, driven by advancements in treatment options and increasing awareness.

**New opportunities:**

- Development of targeted therapies for chordoma subtypes Expansion of telehealth services for patient consultations Investment in biomarker research for personalized treatment plans

By 2035, the chordoma disease market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Diagnosis: Imaging (Largest) vs. Biopsy (Fastest-Growing)

In the US chordoma disease market, the distribution of market share among the diagnosis segment values reveals that Imaging currently holds the largest share, primarily due to its non-invasive nature and effectiveness in providing detailed visuals of tumor locations. It is widely adopted among healthcare professionals, which reinforces its dominant position over competitors such as Biopsy and Blood Tests. Meanwhile, Biopsy is gaining traction as the fastest-growing segment, driven by its accuracy in providing definitive diagnostic results, which appeals to specialists treating chordoma patients.

The growth trends in this segment are influenced by advancements in technology and the increasing focus on early detection and accurate diagnosis. The demand for precise diagnostic tools is pushing developments in Biopsy techniques, leading to its rapid growth. Additionally, Imaging continues to evolve with improved imaging modalities that enhance diagnostic capabilities. The expanding awareness regarding chordoma and its complexities fosters a more robust market, enabling these diagnostic segments to thrive within the US chordoma disease market.

Imaging (Dominant) vs. Biopsy (Emerging)

Imaging stands as the dominant diagnostic technique in the US chordoma disease market, characterized by its ability to deliver detailed images and facilitate non-invasive assessments. Techniques such as MRI and CT scans play a crucial role in evaluating tumor presence and characteristics, making them essential for treatment planning. On the other hand, Biopsy is emerging as a vital method that provides conclusive evidence for diagnoses, capturing tissue samples to ensure accurate treatment approaches. As the demand for reliable and precise diagnostic methods grows, Biopsy is increasingly recognized for its critical role despite its traditionally lower market share compared to Imaging.

### By Treatment: Surgery (Largest) vs. Targeted Therapy (Fastest-Growing)

In the US chordoma disease market, the treatment segment exhibits a diverse array of options, with surgery leading as the largest segment based on current treatment preferences. Chemotherapy and radiation therapy also hold significant shares, but their growth potential is overshadowed by innovations in targeted therapies. Each treatment modality is tailored to specific patient needs, showcasing a spectrum of approaches from traditional surgical methods to advanced targeted options.

Current growth trends indicate a shift towards less invasive treatments, with targeted therapy gaining traction due to its efficacy and patient-centered approach. The increasing understanding of chordoma biology enhances the development of personalized treatments, making targeted therapies an emergent force in the market. Factors such as rising research funding and advancements in medical technology are expected to further fuel this growth, positioning targeted therapy as a vital component of future treatment strategies.

Surgery (Dominant) vs. Targeted Therapy (Emerging)

Surgery remains the dominant treatment method in the US chordoma disease market, primarily due to its direct approach to tumor removal. This traditional technique has established a robust foothold, yet it often necessitates significant recovery time and may not always be suitable for all patients. In contrast, targeted therapy emerges as an innovative and promising alternative, designed to selectively attack cancer cells while sparing healthy tissues. This therapy not only enhances effectiveness but also reduces side effects, appealing to the growing demand for personalized medicine. As research continues to unveil novel targets in chordoma treatment, the market's landscape is likely to shift markedly, making targeted therapies increasingly relevant in conjunction with or as a complement to surgical approaches.

### By End User: Hospital (Largest) vs. Cancer Care Centers (Fastest-Growing)

In the US chordoma disease market, the distribution of market share among end users shows that hospitals account for the largest portion due to their advanced capabilities in treating complex conditions like chordoma. They have the necessary infrastructure, resources, and specialized personnel to provide comprehensive care. Clinics and cancer care centers follow, catering to patients seeking specialized treatment options, but their share is comparatively smaller as they often refer severe cases to hospitals for more intensive interventions.

Growth trends in this segment reveal an increasing shift towards cancer care centers, which are rapidly expanding their services related to chordoma treatment. This shift is driven by a demand for specialized care that is more focused and patient-centered. Technological advancements and an increasing focus on outpatient treatments are also propelling the growth of this segment, allowing cancer care centers to emerge as critical players in the US chordoma disease market.

Hospital (Dominant) vs. Cancer Care Centers (Emerging)

Hospitals remain the dominant force in the US chordoma disease market, characterized by their extensive resources, specialized medical teams, and comprehensive treatment programs. They often have access to advanced technology and multidisciplinary teams that are essential in treating chordoma, which can be complicated due to its location and nature. Meanwhile, cancer care centers are emerging as significant competitors, focusing on tailored treatment plans for chordoma patients. These centers provide a supportive environment and specialized services aimed at improving patient outcomes, making them increasingly attractive for patients seeking more personalized care. This dynamic showcases a shifting landscape where collaboration between hospitals and cancer care centers becomes vital for advancing treatment protocols.

## Competitive Benchmarking

The chordoma disease market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Bristol Myers Squibb (US), Novartis (CH), and Eli Lilly and Company (US) are actively engaged in developing novel therapies and enhancing treatment protocols. Bristol Myers Squibb (US) has focused on immunotherapy advancements, while Novartis (CH) emphasizes targeted therapies, indicating a trend towards precision medicine. Eli Lilly and Company (US) appears to be investing heavily in research and development, particularly in the realm of genetic therapies, which collectively enhances the competitive dynamics of the market.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to improve efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse treatment options but also intensifies competition among key players, as they strive to differentiate their offerings through innovative solutions and strategic collaborations.

In October  Merck & Co. (US) announced a partnership with a leading biotechnology firm to co-develop a novel therapeutic agent specifically targeting chordoma. This collaboration is significant as it not only expands Merck's portfolio but also enhances its research capabilities in a niche area of oncology. The strategic importance of this partnership lies in the potential to accelerate the development of effective treatments, thereby positioning Merck as a leader in the chordoma space.

In September  Pfizer (US) launched a clinical trial for a new drug aimed at treating chordoma, which is currently in Phase II. This move underscores Pfizer's commitment to addressing unmet medical needs in rare cancers. The trial's outcomes could potentially reshape treatment paradigms and solidify Pfizer's standing in the market, as successful results may lead to expedited regulatory approvals.

In August  Amgen (US) expanded its research initiatives by establishing a dedicated team focused on rare tumors, including chordoma. This strategic decision reflects Amgen's recognition of the growing demand for specialized treatments and its intent to leverage its expertise in biotechnology. The establishment of this team may enhance Amgen's innovation pipeline and foster collaborations with academic institutions, further driving advancements in chordoma therapies.

As of November  current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment modalities, and robust supply chain reliability, thereby reshaping the landscape of the chordoma disease market.

## Report Scope

| MARKET SIZE 2024 | 911.4(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 956.15(USD Million) |
| MARKET SIZE 2035 | 1544.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.91% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol Myers Squibb (US), Novartis (CH), Eli Lilly and Company (US), Merck & Co. (US), Amgen (US), Bayer (DE), Pfizer (US), AstraZeneca (GB) |
| Segments Covered | Diagnosis, Treatment, End User |
| Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the chordoma disease market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the chordoma disease market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation for the US chordoma disease market in 2024?**
A: The overall market valuation for the US chordoma disease market was $911.4 Million in 2024.

**Q: What is the projected market valuation for the US chordoma disease market by 2035?**
A: The projected market valuation for the US chordoma disease market is $1544.5 Million by 2035.

**Q: What is the expected CAGR for the US chordoma disease market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US chordoma disease market during the forecast period 2025 - 2035 is 4.91%.

**Q: Which companies are key players in the US chordoma disease market?**
A: Key players in the US chordoma disease market include Bristol Myers Squibb, Novartis, Eli Lilly and Company, Merck & Co., Amgen, Bayer, Pfizer, and AstraZeneca.

**Q: What are the main segments of the US chordoma disease market?**
A: The main segments of the US chordoma disease market include Diagnosis, Treatment, and End User.

**Q: What was the valuation for the Diagnosis segment in the US chordoma disease market in 2024?**
A: The valuation for the Diagnosis segment in the US chordoma disease market was between $200.0 Million and $650.0 Million in 2024.

**Q: What is the projected valuation for the Treatment segment by 2035?**
A: The projected valuation for the Treatment segment in the US chordoma disease market is expected to range from $100.0 Million to $514.5 Million by 2035.

**Q: How much was spent on Imaging in the Diagnosis segment in 2024?**
A: In 2024, spending on Imaging in the Diagnosis segment was between $400.0 Million and $650.0 Million.

**Q: What is the expected valuation for Cancer Care Centers in the End User segment by 2035?**
A: The expected valuation for Cancer Care Centers in the End User segment is projected to be between $261.4 Million and $474.5 Million by 2035.

**Q: What was the valuation for Surgery in the Treatment segment in 2024?**
A: The valuation for Surgery in the Treatment segment was between $300.0 Million and $500.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-chordoma-disease-market-18923*